반응식
[Cl:1][C:2]1[CH:15]=[CH:14][C:5]([CH2:6][N:7]2[CH2:12][CH2:11][CH:10]([NH2:13])[CH2:9][CH2:8]2)=[CH:4][C:3]=1[O:16][CH2:17][CH3:18].[CH:19]([C:22]1[CH:30]=[CH:29][C:25]([C:26](O)=[O:27])=[CH:24][CH:23]=1)([CH3:21])[CH3:20]>>[Cl:1][C:2]1[CH:15]=[CH:14][C:5]([CH2:6][N:7]2[CH2:12][CH2:11][CH:10]([NH:13][C:26](=[O:27])[C:25]3[CH:29]=[CH:30][C:22]([CH:19]([CH3:20])[CH3:21])=[CH:23][CH:24]=3)[CH2:9][CH2:8]2)=[CH:4][C:3]=1[O:16][CH2:17][CH3:18]참가 물질
3
실험 절차
The title compound (7 mg, 17%) was prepared analogously to example 8 by coupling of 1-(4-chloro-3-ethoxy-benzyl)piperidin-4-ylamine with 4-isopropylbenzoic acid. MS: 415.5 (MH+)
출처 및 근거
- ORD 기록
- ord-df4a07273ded4d8aa320ef99a82d1d2c
- 출처 데이터셋
- uspto-grants-2010_08
- 특허 번호
- US07772253B2
연결된 노트
불러오는 중…